Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (<scp>CRSwNP</scp>): A multicentric observational Phase IV real‐life study (<scp>DUPIREAL</scp>)

Our findings from this large-scale real-life study support the effectiveness of dupilumab as an add-on therapy in patients with severe uncontrolled CRSwNP in reducing polyp size and improving the quality of life, severity of symptoms, nasal congestion, and smell.